CTI: Tosedostat on Partial Hold After Death of Patient in Trial
By Randy Osborne
Monday, June 24, 2013
The death of a patient in trials with tosedostat for blood-related cancer cast a pall over Cell Therapeutics Inc.'s shares when investors learned of the partial clinical hold, placed on the compound June 17.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.